日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

Phase II Study of the Liposomal Formulation of Eribulin (E7389-LF) in Combination with Nivolumab: Results from the Gastric Cancer Cohort

脂质体艾立布林（E7389-LF）联合纳武利尤单抗治疗胃癌队列的II期研究结果

期刊:Clinical Cancer Research
影响因子:10.2
doi:10.1158/1078-0432.CCR-23-1768
Kawazoe, Akihito; Yamamoto, Noboru; Sugimoto, Naotoshi; Kawakami, Hisato; Oshima, Takashi; Yamaguchi, Kensei; Hino, Kaori; Hirao, Motohiro; Kurokawa, Yukinori; Kawakami, Takeshi; Tsuda, Masahiro; Hara, Hiroki; Kaname, Shota; Matsuoka, Daiko; Otake, Yohei; Yasuda, Keisuke; Takase, Takao; Takashima, Shuya; Semba, Taro; Muro, Kei
胃癌
肿瘤
肿瘤免疫
发表日期：2024
文献求助 收藏

Phase II Study of the Liposomal Formulation of Eribulin (E7389-LF) in Combination with Nivolumab: Results from the Small Cell Lung Cancer Cohort

脂质体艾立布林（E7389-LF）联合纳武利尤单抗治疗小细胞肺癌队列的II期研究结果

期刊:Cancer Research Communications
影响因子:3.3
doi:10.1158/2767-9764.CRC-23-0313
Nishio, Makoto; Murakami, Shuji; Kawakami, Hisato; Okishio, Kyoichi; Tamiya, Motohiro; Kobayashi, Haruki; Fujimoto, Daichi; Sugawara, Shunichi; Kozuki, Toshiyuki; Oya, Yuko; Izumi, Hiroki; Shiroyama, Takayuki; Satouchi, Miyako; Yamamoto, Noboru; Kaname, Shota; Matsuoka, Daiko; Otake, Yohei; Takase, Takao; Semba, Taro; Azuma, Koichi
肺癌
细胞生物学
肿瘤
肿瘤免疫
发表日期：2024
文献求助 收藏

Phase 1b/2 study of the liposomal formulation of eribulin (E7389-LF) in combination with nivolumab: Results from the phase 2 esophageal cancer cohort

脂质体艾立布林（E7389-LF）联合纳武利尤单抗的1b/2期研究：来自2期食管癌队列的结果

期刊:
影响因子:
doi:10.1038/s44276-024-00066-6
Oshima, Takashi; Yamamoto, Sachiko; Kawakami, Hisato; Makino, Tomoki; Kawazoe, Akihito; Masuishi, Toshiki; Tsushima, Takahiro; Hirao, Motohiro; Tsuda, Masahiro; Hino, Kaori; Yamamoto, Noboru; Hara, Hiroki; Kaname, Shota; Matsuoka, Daiko; Otake, Yohei; Yasuda, Keisuke; Takase, Takao; Takashima, Shuya; Semba, Taro; Ooki, Akira
食管癌
肿瘤
肿瘤免疫
发表日期：2024
文献求助 收藏

Phase I Study of the Liposomal Formulation of Eribulin (E7389-LF): Results from the Advanced Gastric Cancer Expansion Cohort

脂质体艾立布林制剂（E7389-LF）I期研究：来自晚期胃癌扩展队列的结果

期刊:Clinical Cancer Research
影响因子:10.2
doi:10.1158/1078-0432.CCR-22-3027
Shitara, Kohei; Hirao, Motohiro; Iwasa, Satoru; Oshima, Takashi; Komatsu, Yoshito; Kawazoe, Akihito; Sato, Yasuyoshi; Hamakawa, Takuya; Yonemori, Kan; Machida, Nozomu; Yuki, Satoshi; Suzuki, Takuya; Okumura, Shiori; Takase, Takao; Semba, Taro; Zimmermann, Bob; Teng, Angela; Yamaguchi, Kensei
胃癌
肿瘤
肿瘤免疫
发表日期：2023
文献求助 收藏

Phase Ib/II Study of a Liposomal Formulation of Eribulin (E7389-LF) plus Nivolumab in Patients with Advanced Solid Tumors: Results from Phase Ib

艾立布林脂质体制剂（E7389-LF）联合纳武利尤单抗治疗晚期实体瘤患者的Ib/II期研究：Ib期研究结果

期刊:Cancer Research Communications
影响因子:3.3
doi:10.1158/2767-9764.CRC-22-0401
Ida, Hanae; Shimizu, Toshio; Nishino, Makoto; Nakamura, Yoshiaki; Yazaki, Shu; Katsuya, Yuki; Sato, Jun; Koyama, Takafumi; Iwasa, Satoru; Sudo, Kazuki; Kondo, Shunsuke; Yonemori, Kan; Shitara, Kohei; Shiono, Satoshi; Matsuoka, Daiko; Yasuda, Keisuke; Otake, Yohei; Suzuki, Takuya; Takase, Takao; Takashima, Shuya; Yamaguchi, Kohei; Semba, Taro; Yamamoto, Noboru
发表日期：2023
文献求助 收藏

Lenvatinib in combination with golvatinib overcomes hepatocyte growth factor pathway-induced resistance to vascular endothelial growth factor receptor inhibitor.

乐伐替尼与戈伐替尼联合用药可克服肝细胞生长因子通路诱导的对血管内皮生长因子受体抑制剂的耐药性

期刊:Cancer Science
影响因子:4.3
doi:10.1111/cas.12409
Nakagawa Takayuki, Matsushima Tomohiro, Kawano Satoshi, Nakazawa Youya, Kato Yu, Adachi Yusuke, Abe Takanori, Semba Taro, Yokoi Akira, Matsui Junji, Tsuruoka Akihiko, Funahashi Yasuhiro
细胞生物学
血管生成
发表日期：2014
文献求助 收藏